BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 23071688)

  • 1. The DEK oncogene is a target of steroid hormone receptor signaling in breast cancer.
    Privette Vinnedge LM; Ho SM; Wikenheiser-Brokamp KA; Wells SI
    PLoS One; 2012; 7(10):e46985. PubMed ID: 23071688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The DEK oncogene promotes cellular proliferation through paracrine Wnt signaling in Ron receptor-positive breast cancers.
    Privette Vinnedge LM; Benight NM; Wagh PK; Pease NA; Nashu MA; Serrano-Lopez J; Adams AK; Cancelas JA; Waltz SE; Wells SI
    Oncogene; 2015 Apr; 34(18):2325-36. PubMed ID: 24954505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The DEK oncogene activates VEGF expression and promotes tumor angiogenesis and growth in HIF-1α-dependent and -independent manners.
    Zhang Y; Liu J; Wang S; Luo X; Li Y; Lv Z; Zhu J; Lin J; Ding L; Ye Q
    Oncotarget; 2016 Apr; 7(17):23740-56. PubMed ID: 26988756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FOXM1 is a transcriptional target of ERalpha and has a critical role in breast cancer endocrine sensitivity and resistance.
    Millour J; Constantinidou D; Stavropoulou AV; Wilson MS; Myatt SS; Kwok JM; Sivanandan K; Coombes RC; Medema RH; Hartman J; Lykkesfeldt AE; Lam EW
    Oncogene; 2010 May; 29(20):2983-95. PubMed ID: 20208560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic reactivation of estrogen receptor-α (ERα) by genistein enhances hormonal therapy sensitivity in ERα-negative breast cancer.
    Li Y; Meeran SM; Patel SN; Chen H; Hardy TM; Tollefsbol TO
    Mol Cancer; 2013 Feb; 12():9. PubMed ID: 23379261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Wilms' tumor 1 suppressor gene mediates antiestrogen resistance via down-regulation of estrogen receptor-alpha expression in breast cancer cells.
    Han Y; Yang L; Suarez-Saiz F; San-Marina S; Cui J; Minden MD
    Mol Cancer Res; 2008 Aug; 6(8):1347-55. PubMed ID: 18708366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.
    Kuske B; Naughton C; Moore K; Macleod KG; Miller WR; Clarke R; Langdon SP; Cameron DA
    Endocr Relat Cancer; 2006 Dec; 13(4):1121-33. PubMed ID: 17158758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein kinase D1 regulates ERα-positive breast cancer cell growth response to 17β-estradiol and contributes to poor prognosis in patients.
    Karam M; Bièche I; Legay C; Vacher S; Auclair C; Ricort JM
    J Cell Mol Med; 2014 Dec; 18(12):2536-52. PubMed ID: 25287328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anterior gradient-2 plays a critical role in breast cancer cell growth and survival by modulating cyclin D1, estrogen receptor-alpha and survivin.
    Vanderlaag KE; Hudak S; Bald L; Fayadat-Dilman L; Sathe M; Grein J; Janatpour MJ
    Breast Cancer Res; 2010; 12(3):R32. PubMed ID: 20525379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance.
    Imachi H; Murao K; Dobashi H; Bhuyan MM; Cao X; Kontani K; Niki S; Murazawa C; Nakajima H; Kohno N; Yamashita H; Iwase H; Hayashi S; Ishida T; Yamauchi A
    Breast Cancer Res Treat; 2010 Jul; 122(2):395-407. PubMed ID: 19847644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AR collaborates with ERα in aromatase inhibitor-resistant breast cancer.
    Rechoum Y; Rovito D; Iacopetta D; Barone I; Andò S; Weigel NL; O'Malley BW; Brown PH; Fuqua SA
    Breast Cancer Res Treat; 2014 Oct; 147(3):473-85. PubMed ID: 25178514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ERα-positive breast cancer.
    Ciupek A; Rechoum Y; Gu G; Gelsomino L; Beyer AR; Brusco L; Covington KR; Tsimelzon A; Fuqua SA
    Breast Cancer Res Treat; 2015 Nov; 154(2):225-37. PubMed ID: 26487496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leptin interferes with the effects of the antiestrogen ICI 182,780 in MCF-7 breast cancer cells.
    Garofalo C; Sisci D; Surmacz E
    Clin Cancer Res; 2004 Oct; 10(19):6466-75. PubMed ID: 15475434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The human DEK oncogene stimulates β-catenin signaling, invasion and mammosphere formation in breast cancer.
    Privette Vinnedge LM; McClaine R; Wagh PK; Wikenheiser-Brokamp KA; Waltz SE; Wells SI
    Oncogene; 2011 Jun; 30(24):2741-52. PubMed ID: 21317931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. During hormone depletion or tamoxifen treatment of breast cancer cells the estrogen receptor apoprotein supports cell cycling through the retinoic acid receptor α1 apoprotein.
    Salazar MD; Ratnam M; Patki M; Kisovic I; Trumbly R; Iman M; Ratnam M
    Breast Cancer Res; 2011 Feb; 13(1):R18. PubMed ID: 21299862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased BRCA1 confers tamoxifen resistance in breast cancer cells by altering estrogen receptor-coregulator interactions.
    Wen J; Li R; Lu Y; Shupnik MA
    Oncogene; 2009 Jan; 28(4):575-86. PubMed ID: 18997820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Harmful effect of ERβ on BCRP-mediated drug resistance and cell proliferation in ERα/PR-negative breast cancer.
    Li W; Jia M; Qin X; Hu J; Zhang X; Zhou G
    FEBS J; 2013 Dec; 280(23):6128-40. PubMed ID: 24103091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of histone deacetylase enhances the anti-proliferative action of antiestrogens on breast cancer cells and blocks tamoxifen-induced proliferation of uterine cells.
    Hodges-Gallagher L; Valentine CD; Bader SE; Kushner PJ
    Breast Cancer Res Treat; 2007 Nov; 105(3):297-309. PubMed ID: 17186358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Augmentation of estrogen receptor-mediated transcription by steroid and xenobiotic receptor.
    Rokutanda N; Iwasaki T; Odawara H; Nagaoka R; Miyazaki W; Takeshita A; Koibuchi Y; Horiguchi J; Shimokawa N; Iino Y; Morishita Y; Koibuchi N
    Endocrine; 2008 Jun; 33(3):305-16. PubMed ID: 19011999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells.
    Basak P; Chatterjee S; Bhat V; Su A; Jin H; Lee-Wing V; Liu Q; Hu P; Murphy LC; Raouf A
    Cell Physiol Biochem; 2018; 51(4):1518-1532. PubMed ID: 30497079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.